Drug
Azd2936
Azd2936: highest development phase Phase 1/2, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| AZD2936 NCT04995523 | Phase 1/2 | Non-Small-Cell Lung Carcinoma |
Latest
No recent events.
Follow Azd2936 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.